Insys Therapeutics (INSY) Misses Q3 EPS by 6c, Miss on Revenues

Insys Therapeutics (NASDAQ: INSY) reported Q3 EPS of ($0.21), $0.06 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $30.67 million versus the consensus estimate of $36.69 million.

For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.

You May Also Be Interested In

• Piper Sandler sees Google TPU sales hitting $104BN by 2028
• H.B. Fuller (FUL) Tops Q3 EPS by 5c, Misses on Revenue; Offers FY26 EPS Guidance
• Nvidia’s AI dominance funds historic $150 billion buyback